Article(id=1326652890984330140, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652873431167754, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2025.02.002, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1724688000000, receivedDateStr=2024-08-27, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794228297229, onlineDateStr=2026-11-09, pubDate=1739116800000, pubDateStr=2025-02-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794228297229, onlineIssueDateStr=2026-11-09, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794228297229, creator=13701087609, updateTime=1794228297229, updator=13701087609, issue=Issue{id=1326652873431167754, tenantId=1146029695717560320, journalId=1319690329412173987, year='2025', volume='46', issue='2', pageStart='107', pageEnd='210', issueExtLink='null', onlineDate='null', pubDate='1739116800000', pubDateStr='2025-02-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794228293043, creator='13701087609', updateTime=1794273094848, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1326840786227934185, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652873431167754, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1326840786227934186, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652873431167754, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=123, endPage=129, ext={EN=ArticleExt(id=1326652891265348509, articleId=1326652890984330140, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Progress in the development of therapeutic targets and drugs for non-alcoholic steatohepatitis, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=
Non-alcoholic steatohepatitis(NASH), as a chronic metabolic disease, is closely related to obesity, diabetes mellitus type 2, hyperlipidemia and other metabolic syndromes. Its pathogenesis involves multiple factors such as genetics, environment and lifestyle, especially metabolic disorders as the core driving force, which promote disease progression through oxidative stress, endoplasmic reticulum stress and inflammatory pathway activation. For the treatment of NASH, multiple potential therapeutic targets have been identified, such as metabolic regulation, blocking of inflammatory pathways, and anti-fibrosis. NASH may also progress to severe diseases such as cirrhosis and liver cancer, which poses a major threat to human health. In addition, NASH is often accompanied by other metabolic diseases, forming a vicious cycle that further increases the difficulty of treatment and the burden on patients. This article aims to comprehensively review the pathogenesis, therapeutic targets and drug research progress of NASH, and discuss its harm to humans, so as to provide reference for future research and clinical practice.
, authors=Yujie FU
1, 2, Xihui CHEN
1, 2, Minyu LIU
1, 2, *, authorsList=Yujie FU, Xihui CHEN, Minyu LIU, authorCompany=null, correspAuthors=Minyu LIU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1326652891638641566, articleId=1326652890984330140, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=非酒精性脂肪性肝炎治疗靶点及药物研发进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=
非酒精性脂肪性肝炎(non-alcoholic steatohepatitis,NASH)作为一种慢性代谢性疾病,与肥胖、2型糖尿病及高脂血症等代谢综合征密切相关。其发病机制涉及遗传、环境及生活方式等多种因素,特别是代谢紊乱作为核心驱动力,通过氧化应激、内质网应激及炎症通路激活等多种途径促进疾病进展。针对NASH的治疗,已识别出多个潜在的治疗靶点,如代谢调节、炎症通路阻断及抗纤维化等。NASH还可能进展为肝硬化、肝癌等严重疾病,对人类健康构成重大威胁。此外,NASH还常伴其他代谢性疾病,形成恶性循环,进一步加剧治疗难度和患者负担。该文旨在全面综述NASH的发病机制、治疗靶点及药物研究进展,并探讨其对人类的危害,为未来的研究和临床实践提供参考。
, authors=傅宇洁
1, 2, 陈曦慧
1, 2, 刘珉宇
1, 2, *, authorsList=傅宇洁, 陈曦慧, 刘珉宇, authorCompany=null, correspAuthors=刘珉宇, authorNote=
傅宇洁,硕士研究生,研究方向:代谢相关疾病的新药研发。
, correspAuthorsNote=
刘珉宇,研究员,博士生导师,研究方向:自身免疫、代谢、纤维化及抗肿瘤领域。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=+ZZX+zZmjhdleJ2a2xjxoQ==, magXml=GhP7zvfJMa5xuuGmONxzJA==, pdfUrl=null, pdf=wW6zEIxWI3Imzlf89J8XPA==, pdfFileSize=940783, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=XQVI5U5GdvjC1/ior+Aiwg==, mapNumber=null, fund=null)}, authors=[Author(id=1326652892041294758, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652892116792233, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, authorId=1326652892041294758, language=EN, stringName=Yujie FU, firstName=Yujie, middleName=null, lastName=FU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, 2, address=
1.State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
2.Shanghai Professional and Technical Service Center for Biological Material Drug-ability Evaluation, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652892183901098, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, authorId=1326652892041294758, language=CN, stringName=傅宇洁, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, 2, address=
1.中国医药工业研究总院创新药物与制药工艺国家重点实验室,上海 200437
2.上海市生物物质成药性评价技术服务平台,上海 200437, bio={"content":"
傅宇洁,硕士研究生,研究方向:代谢相关疾病的新药研发。
"}, bioImg=null, bioContent=
傅宇洁,硕士研究生,研究方向:代谢相关疾病的新药研发。
, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652891877716895, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, xref=1., ext=[AuthorCompanyExt(id=1326652891886105504, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, companyId=1326652891877716895, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326652891894494113, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, companyId=1326652891877716895, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.中国医药工业研究总院创新药物与制药工艺国家重点实验室,上海 200437)]), AuthorCompany(id=1326652891961602978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, xref=2., ext=[AuthorCompanyExt(id=1326652891974185891, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, companyId=1326652891961602978, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.Shanghai Professional and Technical Service Center for Biological Material Drug-ability Evaluation, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326652891982574500, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, companyId=1326652891961602978, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.上海市生物物质成药性评价技术服务平台,上海 200437)])]), Author(id=1326652892242621356, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652892318118831, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, authorId=1326652892242621356, language=EN, stringName=Xihui CHEN, firstName=Xihui, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, 2, address=
1.State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
2.Shanghai Professional and Technical Service Center for Biological Material Drug-ability Evaluation, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652892389422000, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, authorId=1326652892242621356, language=CN, stringName=陈曦慧, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, 2, address=
1.中国医药工业研究总院创新药物与制药工艺国家重点实验室,上海 200437
2.上海市生物物质成药性评价技术服务平台,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652891877716895, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, xref=1., ext=[AuthorCompanyExt(id=1326652891886105504, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, companyId=1326652891877716895, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326652891894494113, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, companyId=1326652891877716895, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.中国医药工业研究总院创新药物与制药工艺国家重点实验室,上海 200437)]), AuthorCompany(id=1326652891961602978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, xref=2., ext=[AuthorCompanyExt(id=1326652891974185891, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, companyId=1326652891961602978, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.Shanghai Professional and Technical Service Center for Biological Material Drug-ability Evaluation, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326652891982574500, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, companyId=1326652891961602978, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.上海市生物物质成药性评价技术服务平台,上海 200437)])]), Author(id=1326652892456530866, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326652892515251125, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, authorId=1326652892456530866, language=EN, stringName=Minyu LIU, firstName=Minyu, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, 2, *, address=
1.State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
2.Shanghai Professional and Technical Service Center for Biological Material Drug-ability Evaluation, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200437, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652892594942902, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, authorId=1326652892456530866, language=CN, stringName=刘珉宇, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
1, 2, *, address=
1.中国医药工业研究总院创新药物与制药工艺国家重点实验室,上海 200437
2.上海市生物物质成药性评价技术服务平台,上海 200437, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652891877716895, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, xref=1., ext=[AuthorCompanyExt(id=1326652891886105504, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, companyId=1326652891877716895, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326652891894494113, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, companyId=1326652891877716895, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.中国医药工业研究总院创新药物与制药工艺国家重点实验室,上海 200437)]), AuthorCompany(id=1326652891961602978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, xref=2., ext=[AuthorCompanyExt(id=1326652891974185891, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, companyId=1326652891961602978, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.Shanghai Professional and Technical Service Center for Biological Material Drug-ability Evaluation, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326652891982574500, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, companyId=1326652891961602978, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.上海市生物物质成药性评价技术服务平台,上海 200437)])])], keywords=[Keyword(id=1326652892691411895, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, language=EN, orderNo=1, keyword=non-alcoholic steatohepatitis), Keyword(id=1326652892775297976, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, language=EN, orderNo=2, keyword=metabolism), Keyword(id=1326652892842406841, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, language=EN, orderNo=3, keyword=therapeutic targets), Keyword(id=1326652892934681530, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, language=EN, orderNo=4, keyword=progress in drug development), Keyword(id=1326652893001790395, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, language=CN, orderNo=1, keyword=非酒精性脂肪性肝炎), Keyword(id=1326652893081482172, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, language=CN, orderNo=2, keyword=代谢), Keyword(id=1326652894729843646, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, language=CN, orderNo=3, keyword=治疗靶点), Keyword(id=1326652894796952511, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, language=CN, orderNo=4, keyword=药物研发进展)], refs=[Reference(id=1326652894956336064, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=LOOMBA R, FRIEDMAN SL, SHULMAN GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease[J]. Cell, 2021, 184(10): 2537-2564., articleTitle=null, refAbstract=null), Reference(id=1326652895027639233, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHANG S, REN X, ZHANG B,
et al. A systematic review of statins for the treatment of nonalcoholic steatohepatitis:safety, efficacy, and mechanism of action[J]. Molecules, 2024, 29(8): 1859., articleTitle=null, refAbstract=null), Reference(id=1326652895094748098, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=PARK HC, JOO YS, LEE OJ,
et al. Automated classification of liver fibrosis stages using ultrasound imaging[J]. Bio Med Central Med Imaging, 2024, 24(1): 36., articleTitle=null, refAbstract=null), Reference(id=1326652895254131651, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=HARRISON SA, BEDOSSA P, GUY CD,
et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis[J]. N Engl J Med, 2024, 390(6): 497-509., articleTitle=null, refAbstract=null), Reference(id=1326652895329629124, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=YOUNOSSI ZM, GOLABI P, PAIK JM,
et al. The global epidemiology of nonalcoholic fatty liver disease(NAFLD)and nonalcoholic steatohepatitis(NASH): a systematic review[J]. Hepatology, 2023, 77(4): 1335-1347., articleTitle=null, refAbstract=null), Reference(id=1326652895572898757, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=LEE KC, WU PS, LIN HC. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis[J]. Clin Mol Hepatol, 2023, 29(1): 77-98., articleTitle=null, refAbstract=null), Reference(id=1326652895669367750, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=DAS S, RAVI H, BABU A,
et al. Therapeutic potentials of glucose-dependent insulinotropic polypeptide(GIP) in T2DM: past, present, and future[J]. Adv Protein Chem Struct Biol, 2024, 142: 293-328., articleTitle=null, refAbstract=null), Reference(id=1326652895744865223, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=NEWSOME PN, BUCHHOLTZ K, CUSI K,
et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med, 2021, 384(12): 1113-1124., articleTitle=null, refAbstract=null), Reference(id=1326652895807779784, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=LOOMBA R, HARTMAN ML, LAWITZ EJ,
et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis[J]. N Engl J Med, 2024,391(4): 299-310., articleTitle=null, refAbstract=null), Reference(id=1326652895979746249, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=SANYAL AJ, BEDOSSA P, FRAESSDORF M,
et al. A phase 2 randomized trial of survodutide in MASH and fibrosis[J].N Engl J Med, 2024, 391(4): 311-319., articleTitle=null, refAbstract=null), Reference(id=1326652896092992458, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=杨嘉培, 杨桂荣, 秦莲, 等. 运动调控FGF21在改善肥胖相关代谢性疾病中的作用[J]. 生物化学与生物物理进展, 2023,50(11): 2591-2603., articleTitle=null, refAbstract=null), Reference(id=1326652896160101323, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=ABDELMALEK MF, SANYAL AJ, NAKAJIMA A,
et al. Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis(FALCON 2): a randomized phase 2b study[J]. Clin Gastroenterol Hepatol, 2024, 22(1): 113-123., articleTitle=null, refAbstract=null), Reference(id=1326652896218821580, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=HARRISON SA, FRIAS JP, NEFF G,
et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis(HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial[J]. Lancet Gastroenterol Hepatol, 2023, 8(12): 1080-1093., articleTitle=null, refAbstract=null), Reference(id=1326652896277541837, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=LOOMBA R, SANYAL AJ, KOWDLEY KV,
et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH[J]. N Engl J Med, 2023, 389(11):998-1008., articleTitle=null, refAbstract=null), Reference(id=1326652896348845006, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=SCHEEN AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus[J]. Nat Rev Endocrinol, 2020, 16(10): 556-577., articleTitle=null, refAbstract=null), Reference(id=1326652896403370959, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=CHEHREHGOSHA H, SOHRABI MR, ISMAIL-BEIGI F,
et al. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial[J]. Diabetes Ther, 2021, 12(3): 843-861., articleTitle=null, refAbstract=null), Reference(id=1326652896466285520, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=LAI LL, VETHAKKAN SR, NIK MUSTAPHA NR,
et al. Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus[J]. Dig Dis Sci, 2020, 65(2): 623-631., articleTitle=null, refAbstract=null), Reference(id=1326652896541782993, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=MARJOT T, GREEN CJ, CHARLTON CA,
et al. Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes[J]. JGH Open, 2019, 4(3): 433-440., articleTitle=null, refAbstract=null), Reference(id=1326652896608891858, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=陈沛文, 陈晶晶, 应浩, 等. 甲状腺激素受体及其选择性激动剂的研究进展[J]. 中华医学杂志, 2024, 104(20): 1881-1887., articleTitle=null, refAbstract=null), Reference(id=1326652896680195027, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=HARRISON SA, TAUB R, NEFF GW,
et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial[J]. Nat Med, 2023, 29(11):2919-2928., articleTitle=null, refAbstract=null), Reference(id=1326652896768275412, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=GUAN B, TONG J, HAO H,
et al. Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases[J]. Acta Pharm Sin B, 2022, 12(5):2129-2149., articleTitle=null, refAbstract=null), Reference(id=1326652896847967189, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=YOUNOSSI ZM, RATZIU V, LOOMBA R,
et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2019, 394(10215): 2184-2196., articleTitle=null, refAbstract=null), Reference(id=1326652896969602007, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=SANYAL AJ, RATZIU V, LOOMBA R,
et al. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis[J]. J Hepatol, 2023, 79(5):1110-1120., articleTitle=null, refAbstract=null), Reference(id=1326652897057682392, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=DENG YF, HUANG XL, SU M,
et al. Hypolipidemic effect of SIPI-7623, a derivative of an extract from oriental wormwood, through farnesoid X receptor antagonism[J]. Chin J Nat Med, 2018, 16(8): 572-579., articleTitle=null, refAbstract=null), Reference(id=1326652897133179865, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=WAGNER N, WAGNER KD. Recent insights into the role of PPARs in disease[J]. Cells, 2023, 12(12): 1572., articleTitle=null, refAbstract=null), Reference(id=1326652897191900122, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=FRANCQUE SM, BEDOSSA P, RATZIU V,
et al. A randomized, controlled trial of the pan-PPAR agonist Lanifibranor in NASH[J]. N Engl J Med, 2021, 385(17):1547-1558., articleTitle=null, refAbstract=null), Reference(id=1326652897254814683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=DELLI BOVI AP, MARCIANO F, MANDATO C,
et al. Oxidative stress in non-alcoholic fatty liver disease. An updated mini review[J]. Front Med(Lausanne), 2021, 8:595371., articleTitle=null, refAbstract=null), Reference(id=1326652897317729244, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=CHEN G, YU Y, ZHU Y,
et al. Cenicriviroc suppresses and reverses steatohepatitis by regulating macrophage infiltration and M2 polarization in mice[J]. Endocrinology, 2024,165(7): bqae069., articleTitle=null, refAbstract=null), Reference(id=1326652897418392541, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=RATZIU V, SANYAL A, HARRISON SA,
et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study[J]. Hepatology, 2020, 72(3): 892-905., articleTitle=null, refAbstract=null), Reference(id=1326652897481307102, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=ANSTEE QM, NEUSCHWANDER-TETRI BA, WONG V,
et al. Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase Ⅲ randomized study[J]. Clin Gastroenterol Hepatol, 2024, 22(1): 124-134., articleTitle=null, refAbstract=null), Reference(id=1326652897556804575, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=GRUJCIC M, MILOVANOVIC M, NEDELJKOVIC J,
et al. The possible effects of galectin-3 on mechanisms of renal and hepatocellular injury induced by intravascular hemolysis[J]. Int J Mol Sci, 2024, 25(15): 8129., articleTitle=null, refAbstract=null), Reference(id=1326652899226137569, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=CHALASANI N, ABDELMALEK MF, GARCIA-TSAO G,
et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension[J]. Gastroenterology, 2020, 158(5):1334-1345., articleTitle=null, refAbstract=null), Reference(id=1326652899326800866, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=LIAO G, YANG Q, MAO X,
et al. Targeting ASK1 by CS17919 alleviates kidney-and liver-related diseases in murine models[J]. Animal Model Exp Med, 2025, 8(1):102-113., articleTitle=null, refAbstract=null), Reference(id=1326652899398104035, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=LOOMBA R, LAWITZ E, MANTRY PS,
et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial[J]. Hepatology, 2018, 67(2): 549-559., articleTitle=null, refAbstract=null), Reference(id=1326652899490378724, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=HARRISON SA, WONG VW, OKANOUE T,
et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase ⅢSTELLAR trials[J]. J Hepatol, 2020, 73(1): 26-39., articleTitle=null, refAbstract=null), Reference(id=1326652899574264805, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=IKENAGA N, PENG ZW, VAID KA,
et al. Selective targeting of lysyl oxidase-like 2(LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal[J]. Gut, 2017,66(9): 1697-1708., articleTitle=null, refAbstract=null), Reference(id=1326652899662345190, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=HARRISON SA, ABDELMALEK MF, CALDWELL S,
et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis[J]. Gastroenterology, 2018, 155(4): 1140-1153., articleTitle=null, refAbstract=null), Reference(id=1326652899742036967, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=KIM CW, ADDY C, KUSUNOKI J,
et al. Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation[J]. Cell Metab, 2017, 26(2): 394-406., articleTitle=null, refAbstract=null), Reference(id=1326652899825923048, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=CALLE RA, AMIN NB, CARVAJAL-GONZALEZ S,
et al. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase Ⅱa trials[J]. Nat Med, 2021, 27(10): 1836-1848., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1326652891877716895, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, xref=1., ext=[AuthorCompanyExt(id=1326652891886105504, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, companyId=1326652891877716895, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326652891894494113, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, companyId=1326652891877716895, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
1.中国医药工业研究总院创新药物与制药工艺国家重点实验室,上海 200437)]), AuthorCompany(id=1326652891961602978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, xref=2., ext=[AuthorCompanyExt(id=1326652891974185891, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, companyId=1326652891961602978, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.Shanghai Professional and Technical Service Center for Biological Material Drug-ability Evaluation, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200437, China), AuthorCompanyExt(id=1326652891982574500, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652890984330140, companyId=1326652891961602978, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=
2.上海市生物物质成药性评价技术服务平台,上海 200437)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li {
margin-right: 18px;
}
@media (max-width: 1442px) {
.style-1 .main-menu ul>li a {
font-size: 16px;
padding: 10px 0;
}
}, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li {
margin-right: 18px;
}
@media (max-width: 1442px) {
.style-1 .main-menu ul>li a {
font-size: 16px;
padding: 10px 0;
}
}, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.02.002, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.02.002, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2025.02.002, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2025.02.002, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1739116800000, fullTextJson=null, articleText=null, reference=null)